Guaifenesin + Diphenhydramine Hydrochloride + Bromhexine + Phenylpropanolamine HydrochlorideThird Party Manufacturing in India

This quad-combination syrup works through four complementary pharmacological actions to provide comprehensive symptomatic relief from cough, congestion, and upper respiratory discomfort. Guaifenesin acts as an expectorant by increasing the volume and reducing the viscosity of bronchial secretions through stimulation of vagal nerve endings in the gastric mucosa. This reflex enhances the production of thinner, less tenacious mucus that is more easily cleared by productive cough, improving airway patency and mucociliary clearance. Diphenhydramine Hydrochloride is a first-generation antihistamine that competitively blocks histamine H1 receptors, suppressing histamine-mediated allergic responses including sneezing, rhinorrhea, nasal pruritus, and bronchospasm. Its central anticholinergic activity further contributes to its antitussive effect by elevating the cough threshold in the medullary cough center. Bromhexine functions as a mucolytic agent by depolymerizing acid mucopolysaccharide fibers within bronchial secretions, breaking down thick, viscid sputum into thinner, less cohesive material that is easier to expectorate. Phenylpropanolamine Hydrochloride exerts its decongestant action through direct stimulation of alpha-1 adrenergic receptors in the nasal and respiratory mucosa, producing vasoconstriction that reduces tissue edema, nasal congestion, and sinus pressure while restoring upper airway patency.

Therapeutic Uses

This combination syrup is indicated for the symptomatic relief of cough and respiratory congestion associated with common cold, allergic rhinitis, and upper respiratory tract infections:

• Productive Cough with Congestion: Loosens thick mucus while reducing nasal congestion, allowing patients to clear secretions more effectively
• Allergic Rhinitis with Cough: Addresses both histamine-mediated nasal symptoms and associated cough through the combined action of antihistamine and expectorant
• Acute Bronchitis: Provides symptomatic relief from cough, chest congestion, and associated nasal obstruction during acute episodes
• Sinusitis: Reduces nasal mucosal edema and promotes drainage of the paranasal sinuses while managing post-nasal drip-induced cough

Why Manufacturers Choose Guaifenesin + Diphenhydramine + Bromhexine + Phenylpropanolamine

This quad-combination formulation occupies a strong position in the Indian cough and cold market, where combination products are widely prescribed for comprehensive symptom relief. The syrup formulation is particularly popular in the paediatric and geriatric segments, where multi-symptom cough preparations are a mainstay of treatment. The combination addresses all major cough and cold symptoms—expectoration, antihistamine action, mucolysis, and decongestion—within a single product, reducing the need for polypharmacy.

For manufacturers, this formulation offers clear advantages in the PCD franchise segment, where differentiated combination products command better margins than single-molecule cough syrups. All four APIs are readily available from domestic suppliers, and the formulation process for oral liquids is well established in Indian WHO-GMP facilities. The product enjoys steady year-round demand that spikes during seasonal respiratory illness peaks, providing both consistent baseline volume and seasonal upside. It is also well suited for institutional supply to hospitals and nursing homes that stock comprehensive cough and cold ranges.

This makes this combination one of the most sought-after formulations for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.